Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03984448 |
| Title | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas |
| Recruitment | Suspended |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | National Cancer Institute (NCI) |
| Indications | |
| Therapies |
Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate |
| Age Groups: | senior | adult |
| Covered Countries | USA |